Long-term safety of Afimkibart for eczema patients
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests the long-term safety and effectiveness of a medicine called Afimkibart for people with atopic dermatitis (eczema). It is for people who already completed a previous study of this medicine and had at least a 50% improvement in their eczema.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the main (parent) study of this drug and made it to the Week 36 follow-up visit.
- You must have had at least a 50% improvement in your eczema since the start of the parent study.
- You cannot have other skin conditions that would make it hard to tell whether the drug is working for your eczema.
- You must not have withdrawn from or stopped the main study early.
- You should not have a history of severe allergic reactions to biologic drugs or to this study medicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new investigational medicine (PF-07832837) for safety in healthy adults and in people with moderate to severe atopic dermatitis (eczema). It is a first-in-human study, so it looks at how well the body tolerates the medicine.
This study tests the long-term safety and effectiveness of abrocitinib (Cibinqo) for children aged 6 to 12 with moderate to severe eczema that hasn't improved with creams. It may help their skin clear and reduce itching.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This study tests a new medicine called Stapokibart for children aged 2 to 11 with moderate-to-severe atopic dermatitis (also called eczema) that hasn't improved with topical creams. The medicine is given as an injection and may help reduce itching and skin symptoms.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.